MS Views and News Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, CLICK HERE - -

Visit our MS learning channel on YouTube, which provides hundreds of MS educational videos presented by MS Experts from across the USA. Archived here: -- Also please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for the MS community. Furthermore, scroll down the left side of this blog to learn from the resources and links.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Wednesday, July 19, 2017

MMJ BioScience Developing New Multiple Sclerosis Drug

Click here to receive MS news via e-mail

Posted: Jul 19, 2017 4:03 AM EDT
MMJ BioScience is developing one of the first pharmaceutical formulations of cannabidiol (CBD) derived from certain extracts of the cannabis plant. MMJ Bio Science is also beginning Phase 2 studies with a new drug for the treatment of primary progressive multiple sclerosis.
Buffalo, New York (PRWEB) July 19, 2017
MMJ International Holdings, the premier medical cannabis research company that is advancing the science of medical marijuana through patient clinical research and operation of medical cannabis healthcare businesses, today announced that its affiliate MMJ Bioscience, is developing the first pharmaceutical formulation of cannabidiol (CBD) derived from certain extracts of the cannabis plant. MMJ BioScience is also currently beginning Phase 2 studies with a new drug for the treatment of primary progressive multiple sclerosis.
"Multiple sclerosis (MS) is a disease that interferes with your brain's ability to operate your body and it can be disabling. Evidence suggests that the disease happens when your immune system attacks a substance called myelin" stated Denis Harris, MD. "The myelin acts as a type of insulation on your nerve cells. This process can lead to damage in and around the nerves in your brain and spinal cord".
Dr. Harris further stated that "a large percentage of these patients are resistant to currently available treatments and experience multiple symptoms including spasticity and pain. These conditions are difficult to manage and treatment options are currently limited, particularly in PPMS for which there are currently only one FDA-approved treatment.The day-to-day impact of these devastating conditions are significant and, with high rates of mortality."
The MMJ Bio Science team is creating a pipeline of clinical-stage cannabinoid candidates for both orphan and non-orphan indications with a focus on MS neurological conditions.
The cannabis plant contains more than 100 cannabinoids; the two best characterized are CBD and tetrahydrocannabinol (THC). CBD is a non-psychoactive component of the cannabis plant which, in clinical
trials, has shown medical benefit. CBD is being studied for a number of chronic conditions, including multiple sclerosis, due to its potential anti spastic properties. CBD is unlike THC, the component of the marijuana plant that makes people “high.”The fact is that MMJ Bio Science is utilizing a purified pharmaceutical formulation of plant-derived CBD is of particular importance as MMJ BioScience’s formulation is expected to be an indicated use in adults patients with MS.
Pharmaceutical CBD is a consistent, standardized formulation of CBD that meets chemical purity and quality measures and is studied in randomized, controlled clinical trials with oversight from a recognized regulatory authority, such as the U.S. Food and Drug Administration (FDA) to ensure safety and efficacy. To date, there are no plant-derived THC & CBD products that meet FDA standards.
MMJ BioScience’s formulation IS NOT MEDICAL MARIJUANA

MS Views and News is MAKING an IMPACT for those, affected by Multiple Sclerosis
MS Views and News provides beneficial Multiple Sclerosis education, information, resources and services. 
Join us, opt-in here: 

No comments: